

Lapatinib EGF104900

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



No significant QoL benefit



Serious and disabling adverse effects



Other adjustments



Lapatinib EGF104900

FINAL SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Therapeutic Indication: Treatment of patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with trastuzumab for patients with HR-metastatic disease that has progressed on prior trastuzumab therapy of therapies in combination with ChT  
Experimental Arm: Lapatinib + Trastuzumab  
Control Arm: Lapatinib



